半相合细胞移植对CT-26结肠癌荷瘤小鼠的抑瘤作用

Abstract
Figure/Table
References (0)
Related Citation (1)

Download: PDF (12188 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract Objective: To investigate the effect of grafts transplanted with haploidentical cells on CT-26 colon cancer cells in tumor-bearing mice and its potential mechanism. Methods: The spleen cells and bone marrow cells of C57BL/6 mice were taken as donor cells; 18 CB6F1 mice(receptor) were taken and randomly divided into control group, cyclophosphamide group and transplantation group, 6 mice in each group, and subcutaneously implanted mouse colon cancer CT26 cells to establish subcutaneous tumorbearing mouse model; then 0.2 mL of normal saline, cyclophosphamide, cyclophosphamide+spleen cells+bone marrow cells were injected into the tail vein for 4 consecutive weeks; the tumor volumes of the three groups mice were detected at different time points; tumor, liver, small intestine and skin tissues of three groups mice were harvested at 2 weeks, and the pathological changes were observed by HE staining; contents of IL2, IL-4, IL-10, IFN-γ, TNF-α and TGF-β in mouse tumor tissues were detected by ELISA. The chimerism rate of peripheral blood cells (H-2Kd/b) in the transplantation group at 3 days, 2 weeks and 4 weeks was detected by flow cytometry. Results: At the 2-week, the tumor volume in the cyclophosphamide group and the transplantation group was significantly smaller than that in the control group(both P<0.01). Compared with the control group and cyclophosphamide group, the contents of IL-2, IL-10, IFN-γ and TNF-α in tumor tissues of the transplantation group were significantly increased(all P<0.05), while the contents of IL-4 and TGF-β were significantly decreased(both P<0.05). Compared with those at 3-day, the proportion of H-2Kb in peripheral blood of CB6F1 mice was significantly increased at 2- and 4-week(both P<0.01). Conclusion: Splenocytes and bone marrow cells derived from C57BL/6(H2Kb) mice exerted an anticolorectal cancer effect on tumorbearing mice by changing the immune microenvironment of CB6F1(H-2Kd/b) mice.

Key words：

Received: 06 May 2021

Fund:

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHUANSUN Xuemei
	ZHOU Qing
	SUN Maomin

Cite this article:

ZHUANSUN Xuemei,ZHOU Qing,SUN Maomin. Inhibitory effect of semi-compatible cell transplantation on CT-26 colon cancer cells in tumorbearing mice[J]. Journal of Jiangsu University(Medicine Edition), 2022, 32(02): 136-140.

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2022/V32/I02/136

［1］Brody H. Colorectal cancer［J］. Nature, 2015, 521(7551): S1.
［2］Dekker E, Tanis PJ, Vleugels Jasper LA, et al. Colorectal cancer［J］. Lancet, 2019, 394(10207): 1467-1480.
［3］Jenq RR, Van Den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer［J］. Nat Rev Cancer, 2010, 10(3): 213-221.
［4］Blazar BR, Hill GR, Murphy WJ. Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD［J］. Nat Rev Clin Oncol, 2020, 17(8): 475-492.
［5］Negrin RS. Introduction to the review series on “Advances in hematopoietic cell transplantation”［J］. Blood, 2014, 124(3): 307.
［6］Parmar S, Ritchie DS. Allogeneic transplantation as anticancer immunotherapy［J］. Curr Opin Immunol, 2014, 27: 38-45.
［7］Fleischhauer K, Beelen DW. HLA mismatching as a strategy to reduce relapse after alternative donor transplantation［J］. Semin Hematol, 2016, 53(2): 57-64.
［8］Carniti C, Gimondi S, Vendramin A, et al. Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects［J］. Clin Cancer Res, 2015, 21(16): 3740-3749.
［9］Zilberberg J, Feinman R, Korngold R. Strategies for the identification of T cellrecognized tumor antigens in hematological malignancies for improved graftversustumor responses after allogeneic blood and marrow transplantation［J］. Biol Blood Marrow Transplant, 2015, 21(6): 1000-1007.
［10］Wang H, Yang YG. The complex and central role of interferonγ in graftversushost disease and graftversustumor activity［J］. Immunol Rev, 2014, 258(1): 30-44.
［11］De Casterle ID, Billiau AD, Sprangers B. Recipient and donor cells in the graftversussolid tumor effect: It takes two to tango［J］. Blood Rev, 2018, 32(6): 449-456.
［12］Renga M, Pedrazzoli P, Siena S. Present results and perspectives of allogeneic nonmyeloablative hematopoietic stem cell transplantation for treatment of human solid tumors［J］. Ann Oncol, 2003, 14(8): 1177-1184.
［13］Ghimire S, Weber D, Mavin E, et al.Pathophysiology of GVHD and other HSCTrelated major complications［J］. Front Immunol, 2017, 8: 79.
［14］Fridman WH, Zitvogel L, SautesFridman C, et al. The immune contexture in cancer prognosis and treatment［J］. Nat Rev Clin Oncol, 2017, 14(12): 717-734.
［15］Yu D, Wang L, Wu T, et al. Graftversustumor effect in major histocompatibility complexmismatched mouse liver transplantation［J］. Liver Transpl, 2019, 25(8): 1251-1264.
［16］Josephs DH, Bax HJ, Karagiannis SN. Tumourassociated macrophage polarisation and reeducation with immunotherapy［J］. Front Biosci (Elite Ed), 2015, 7: 293-308.
［17］Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer［J］. Cancer Cell, 2015, 27(4): 462-472.
［18］Zhanna Y, Ester H, Lola W, et al. Multidonor bone marrow transplantation improves donor engraftment and increases the graft versus tumor effect while decreasing graftversushost disease［J］. Transpl Int, 2011, 24(2): 194-200.
［19］Robert S, Albring JC, Frebel K, et al. Alloantigen expression on malignant cells and healthy host tissue influences graftversustumor reactions after allogeneic hematopoietic stem cell transplantation［J］. Bone Marrow Transplant, 2018, 53(7): 807-819.